Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial.

Magosso E, Ansari MA, Gopalan Y, Shuaib IL, Wong JW, Khan NA, Abu Bakar MR, Ng BH, Yuen KH.

Nutr J. 2013 Dec 27;12(1):166. doi: 10.1186/1475-2891-12-166.

2.

Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.

Askari F, Rashidkhani B, Hekmatdoost A.

Nutr Res. 2014 Feb;34(2):143-8. doi: 10.1016/j.nutres.2013.11.005. Epub 2013 Dec 6.

PMID:
24461315
3.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462
4.

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.

Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW.

World J Gastroenterol. 2008 Nov 7;14(41):6395-400.

5.

Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers.

Sesti G, Fiorentino TV, Hribal ML, Sciacqua A, Perticone F.

Nutr Metab Cardiovasc Dis. 2013 Dec;23(12):1182-7. doi: 10.1016/j.numecd.2013.01.006. Epub 2013 Feb 15.

PMID:
23419734
6.

Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.

Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S.

Nutr Clin Pract. 2013 Feb;28(1):101-11. doi: 10.1177/0884533612454884. Epub 2012 Oct 5.

PMID:
23042833
7.

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.

Faghihzadeh F, Adibi P, Hekmatdoost A.

Br J Nutr. 2015 Sep 14;114(5):796-803. doi: 10.1017/S0007114515002433. Epub 2015 Aug 3.

PMID:
26234526
8.

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A.

Aliment Pharmacol Ther. 2006 Apr 15;23(8):1143-51.

9.

[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].

Zhang DM, Zhang GY, Wang T, Zhong HJ, Chen WK.

Zhonghua Yi Xue Za Zhi. 2006 May 16;86(18):1279-83. Chinese.

PMID:
16796890
10.

Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India.

Nigam P, Bhatt SP, Misra A, Vaidya M, Dasgupta J, Chadha DS.

PLoS One. 2013;8(1):e49286. doi: 10.1371/journal.pone.0049286. Epub 2013 Jan 11.

11.

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network..

JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520.

12.

Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease.

Illnait J, Rodríguez I, Mendoza S, Fernández Y, Mas R, Miranda M, Piñera J, Fernández JC, Mesa M, Fernández L, Carbajal D, Gámez R.

Korean J Intern Med. 2013 Jul;28(4):439-48. doi: 10.3904/kjim.2013.28.4.439. Epub 2013 Jul 1.

13.

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.

Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A.

Aliment Pharmacol Ther. 2001 Oct;15(10):1667-72.

14.

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.

Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30.

PMID:
23727264
15.

Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.

Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, Mazur A, Neuhoff-Murawska J, Matusik P, Socha P.

J Pediatr. 2015 Jun;166(6):1358-63.e1-3. doi: 10.1016/j.jpeds.2015.01.056. Epub 2015 Mar 11.

PMID:
25771388
16.

Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.

Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J.

Eur Rev Med Pharmacol Sci. 2011 Sep;15(9):1090-5.

PMID:
22013734
17.

Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.

Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli C, Agostoni C.

Arch Dis Child. 2011 Apr;96(4):350-3. doi: 10.1136/adc.2010.192401. Epub 2011 Jan 12.

PMID:
21233083
18.

Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA.

J Am Coll Nutr. 2016 May-Jun;35(4):346-53. doi: 10.1080/07315724.2015.1021057. Epub 2015 Jul 9.

PMID:
26156412
19.

Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy.

de Piano A, Tock L, Carnier J, Oyama LM, Oller do Nascimento CM, Martinz AC, Foschini D, Sanches PL, Ernandes RM, de Mello MT, Tufik S, Dâmaso AR.

Metabolism. 2010 May;59(5):613-9. doi: 10.1016/j.metabol.2009.09.003. Epub 2009 Nov 26.

PMID:
19942238
20.

In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.

Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A.

Metabolism. 2013 Mar;62(3):352-60. doi: 10.1016/j.metabol.2012.08.005. Epub 2012 Sep 19.

PMID:
22999011

Supplemental Content

Support Center